Why this exists

Step five establishes that dose requirements vary roughly thirteen-fold between individuals, with genetic differences in hepatic metabolism accounting for three-fold or more on their own. The operational consequence is that some proportion of the patients flagged by any dose threshold are not outliers in behavior. They are outliers in pharmacology.

Today those two groups look identical in the data. A patient who is a CYP2D6 poor metabolizer taking what appears to be a high dose, and a patient acquiring more than they need, generate the same number. The first one is then subjected to the interventions designed for the second.

The purpose here is to tell them apart — and specifically to give the first group an explanation that exists in the record before anybody has to defend it.

How it works

• Pharmacokinetic and metabolic characterization where the clinical picture does not match the dose, so that a discrepancy has a documented cause.
• Co-medication review for interaction effects, which matter as much as genotype. A controlled crossover study in genotyped healthy volunteers found that blocking CYP3A had a major effect on every pharmacodynamic measure for oxycodone — the variability is not CYP2D6 alone.
• Documented in the clinical record, so the explanation travels with the patient to the next clinician, the next pharmacy and the next reviewer.

It is not a dose calculator. No genotype tells you what dose a person needs, and CPIC says so directly.

It is not a screening test for misuse. Metabolic status is a fact about a person’s enzymes. It carries no information about their behavior and must never be presented as if it does.

It is not a gate. A patient who declines testing is not thereby treated as an unexplained outlier; the absence of a test is not evidence of anything.

Questions this raises

Can a genetic test tell you the right opioid dose?

No. The Clinical Pharmacogenetics Implementation Consortium makes no dosing recommendation based on OPRM1 or COMT genotype and gives no recommendation for oxycodone or methadone. What it does support is drug selection — avoiding codeine and tramadol in CYP2D6 poor and ultrarapid metabolizers. See what pharmacogenomics can and cannot do.

If trials show no outcome benefit, why include this at all?

Because the trials tested a different question. They asked whether genotype-guided prescribing improves pain scores in largely postoperative, multimodal settings. This component asks whether an existing unusual dose has a pharmacological explanation that should be in the record. That is a documentation and drug-selection use, not a dose-prediction use, and we are explicit that the second is unproven. See the evidence page.